PL2480546T3 - Pochodne imidazopirydyny i imidazopirymidyny jako inhibitory fosfodiesterazy 10A - Google Patents

Pochodne imidazopirydyny i imidazopirymidyny jako inhibitory fosfodiesterazy 10A

Info

Publication number
PL2480546T3
PL2480546T3 PL10760968T PL10760968T PL2480546T3 PL 2480546 T3 PL2480546 T3 PL 2480546T3 PL 10760968 T PL10760968 T PL 10760968T PL 10760968 T PL10760968 T PL 10760968T PL 2480546 T3 PL2480546 T3 PL 2480546T3
Authority
PL
Poland
Prior art keywords
imidazopyridine
phosphodiesterase
inhibitors
imidazopyrimidine derivatives
imidazopyrimidine
Prior art date
Application number
PL10760968T
Other languages
English (en)
Inventor
Daniela Alberati
Sánchez Rubén Alvarez
Konrad Bleicher
Alexander Flohr
Zbinden Katrin Groebke
Matthias Koerner
Bernd Kuhn
Jens-Uwe Peters
Markus Rudolph
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PL2480546T3 publication Critical patent/PL2480546T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/5025Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Addiction (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PL10760968T 2009-09-24 2010-09-21 Pochodne imidazopirydyny i imidazopirymidyny jako inhibitory fosfodiesterazy 10A PL2480546T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09171253 2009-09-24
EP10760968.7A EP2480546B1 (en) 2009-09-24 2010-09-21 Imidazopyridine or imidazopyrimidine derivatives as phosphodiesterase 10A inhibitors
PCT/EP2010/063830 WO2011036127A1 (en) 2009-09-24 2010-09-21 Imidazopyridine or imidazopyrimidine derivatives as phosphodiesterase 10a inhibitors

Publications (1)

Publication Number Publication Date
PL2480546T3 true PL2480546T3 (pl) 2015-05-29

Family

ID=43416552

Family Applications (1)

Application Number Title Priority Date Filing Date
PL10760968T PL2480546T3 (pl) 2009-09-24 2010-09-21 Pochodne imidazopirydyny i imidazopirymidyny jako inhibitory fosfodiesterazy 10A

Country Status (23)

Country Link
US (2) US8017604B2 (pl)
EP (1) EP2480546B1 (pl)
JP (1) JP5629322B2 (pl)
KR (1) KR101426624B1 (pl)
CN (1) CN102548991B (pl)
AR (1) AR078437A1 (pl)
BR (1) BR112012006531A2 (pl)
CA (1) CA2770087C (pl)
CL (1) CL2012000708A1 (pl)
CY (1) CY1116120T1 (pl)
DK (1) DK2480546T3 (pl)
ES (1) ES2530884T3 (pl)
HR (1) HRP20150345T1 (pl)
IL (1) IL218032A (pl)
MX (1) MX2012003469A (pl)
PE (1) PE20121438A1 (pl)
PH (1) PH12012500355A1 (pl)
PL (1) PL2480546T3 (pl)
PT (1) PT2480546E (pl)
RU (1) RU2502737C2 (pl)
SI (1) SI2480546T1 (pl)
TW (1) TWI402268B (pl)
WO (1) WO2011036127A1 (pl)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8470820B2 (en) * 2010-01-22 2013-06-25 Hoffman-La Roche Inc. Nitrogen-containing heteroaryl derivatives
CN103298468A (zh) 2011-02-01 2013-09-11 协和发酵麒麟株式会社 稠环杂环衍生物
KR20140009372A (ko) 2011-02-18 2014-01-22 알러간, 인코포레이티드 포스포다이에스테라제 10(pde10a)의 억제제로서의 치환된 6,7-다이알콕시-3-아이소퀴놀리놀 유도체
US8975276B2 (en) 2011-06-29 2015-03-10 Bristol-Myers Squibb Company Inhibitors of PDE10
EP2574607A1 (en) 2011-09-06 2013-04-03 F. Hoffmann-La Roche AG PDE10 modulators
PE20141553A1 (es) * 2011-09-19 2014-10-30 Hoffmann La Roche Compuestos de triazolopiridina como inhibidores de la ped10a
WO2014071044A1 (en) 2012-11-01 2014-05-08 Allergan, Inc. Substituted 6,7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (pde10a)
WO2014118039A1 (en) * 2013-01-31 2014-08-07 F. Hoffmann-La Roche Ag Radiolabeled compounds
EP2963037B1 (en) 2013-02-27 2019-03-27 Mochida Pharmaceutical Co., Ltd. Novel pyrazole derivative
RU2015147450A (ru) 2013-04-29 2017-06-05 Ф. Хоффманн-Ля Рош Аг ПРОИЗВОДНЫЕ 2-ФЕНИЛ ИЛИ 2-ГЕТЕРОАРИЛ ИМИДАЗОЛ[1,2-a]ПИРИДИНА
DK2991984T3 (en) * 2013-04-30 2017-05-08 Hoffmann La Roche PALLADIUM-CATALYST COUPLING OF PYRAZOLAMIDES
WO2015006689A1 (en) 2013-07-12 2015-01-15 University Of South Alabama Treatment and diagnosis of cancer and precancerous conditions using pde10a inhibitors and methods to measure pde10a expression
JP6182668B2 (ja) * 2013-09-26 2017-08-16 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 画像化ツールとしてのイミダゾ[1,2−a]ピリジン−7−アミン
US9200016B2 (en) 2013-12-05 2015-12-01 Allergan, Inc. Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A)
MY199759A (en) 2016-09-02 2023-11-21 Tisento Therapeutics Inc Fused bicyclic sgc stimulators
CN113698406A (zh) * 2021-08-30 2021-11-26 成都药明康德新药开发有限公司 6-甲基吡唑并[1,5-a]嘧啶-3-胺的合成方法
AR134414A1 (es) * 2023-11-21 2026-01-14 Novartis Ag Imidazoarenos sustituidos y métodos para su uso

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA01007019A (es) * 1999-11-10 2002-09-18 Johnson & Johnson 2-aril-3-(heteroaril)-imidazo[1,2-a]pirimidinas, sustituidas y composiciones farmaceuticas relacionados y metodos.
SE0102808D0 (sv) * 2001-08-22 2001-08-22 Astrazeneca Ab New compounds
JP4449746B2 (ja) * 2002-07-12 2010-04-14 アステラス製薬株式会社 N−フェニル−(2r,5s)ジメチルピペラジン誘導体
EP1570847B1 (en) * 2002-12-03 2012-04-25 Kyorin Pharmaceutical Co., Ltd. Phosphodiesterase 10a inhibitors for use in the treatment of parkinson's disease, huntington's disease and schizophrenia
WO2005012485A2 (en) 2003-07-31 2005-02-10 Bayer Pharmaceuticals Corporation Methods for treating diabetes and related disorders using pde10a inhibitors
EP1748048A4 (en) * 2004-05-10 2010-05-26 Banyu Pharma Co Ltd imidazopyridine
AU2006218403A1 (en) * 2005-03-03 2006-09-08 Sirtris Pharmaceuticals, Inc. Fused heterocyclic compounds and their use as sirtuin modulators
AU2007207053B2 (en) * 2006-01-17 2012-05-24 F. Hoffmann-La Roche Ag Aryl-isoxazol-4-yl-imidazo[1,2-a]pyridine useful for the treatment of Alzheimer's disease via GABA receptors
AU2007217750A1 (en) * 2006-02-21 2007-08-30 Amgen Inc. Cinnoline derivatives as phosphodiesterase 10 inhibitors
DE102007012645A1 (de) * 2007-03-16 2008-09-18 Bayer Healthcare Ag Substituierte Imidazo- und Triazolopyrimidine
FR2926556B1 (fr) * 2008-01-22 2010-02-19 Sanofi Aventis Derives de carboxamides n-azabicycliques, leur preparation et leur application en therapeutique

Also Published As

Publication number Publication date
EP2480546B1 (en) 2014-12-31
CN102548991A (zh) 2012-07-04
IL218032A0 (en) 2012-04-30
PT2480546E (pt) 2015-02-09
TW201116530A (en) 2011-05-16
DK2480546T3 (en) 2015-02-02
US8017604B2 (en) 2011-09-13
ES2530884T3 (es) 2015-03-06
AR078437A1 (es) 2011-11-09
MX2012003469A (es) 2012-04-19
JP2013505911A (ja) 2013-02-21
US8263584B2 (en) 2012-09-11
CL2012000708A1 (es) 2012-09-07
US20110071128A1 (en) 2011-03-24
RU2502737C2 (ru) 2013-12-27
CA2770087C (en) 2014-09-09
PE20121438A1 (es) 2012-10-26
BR112012006531A2 (pt) 2016-11-22
WO2011036127A1 (en) 2011-03-31
KR101426624B1 (ko) 2014-08-05
PH12012500355A1 (en) 2019-11-29
HRP20150345T1 (hr) 2015-05-08
KR20120068943A (ko) 2012-06-27
TWI402268B (zh) 2013-07-21
CA2770087A1 (en) 2011-03-31
US20110294779A1 (en) 2011-12-01
CY1116120T1 (el) 2017-02-08
AU2010299927A1 (en) 2012-03-15
SI2480546T1 (sl) 2015-03-31
RU2012113128A (ru) 2013-11-10
CN102548991B (zh) 2015-03-25
IL218032A (en) 2014-06-30
EP2480546A1 (en) 2012-08-01
JP5629322B2 (ja) 2014-11-19

Similar Documents

Publication Publication Date Title
PL2480546T3 (pl) Pochodne imidazopirydyny i imidazopirymidyny jako inhibitory fosfodiesterazy 10A
PL2504336T3 (pl) Nowe pochodne naftyrydynowe i ich zastosowanie jako inhibitorów kinaz
PL2456444T3 (pl) Pochodne adeniny jako inhibitory PI3K
FR20C1030I2 (fr) Inhibiteurs de beta-lactamase
BRPI0916295A2 (pt) inibidores de pirazolopiridina tricíclica cinase
IL219916A0 (en) Imidazopyridine derivatives as jak inhibitor
PL2927213T3 (pl) Pochodne piperydynonu jako inhibitory MDM2 do leczenia nowotworu
SMT201600104B (it) Inibitore di bromodominio benzodiazepinico
BRPI0913580A2 (pt) pirrolopiridinas como inibidores de quinase
BRPI0814065A2 (pt) Derivados de alcoóis de 1-fenil-2-piridinil alquila como inibidores da fosfodiesterase
SMT201400123B (it) Imidazo[1,2B]piridazine sostituite come inibitori di trk-chinasi
EP2391627A4 (en) BICYCLIC PYRAZOLO HETEROCYCLES
BR112012008108A2 (pt) derivados de xantina substituídos
DK2376490T3 (da) Imidazopyridinforbindelser
PT2536730E (pt) Compostos pirrolopirimidina enquanto inibidores de cdk4/6
PL2649076T3 (pl) Makrocyklowe inhibitory wirusów Flaviviridae
BRPI1011066A2 (pt) "pirazolopirimidinas e heterociclos relacionados como inibidores de quinase
IL212285A0 (en) Azaindole derivatives
IL212842A0 (en) Azaindole derivatives as kinase inhibitors
BRPI0914301A2 (pt) derivados de pirimidin-4-ona substituída
GB201016880D0 (en) Phosphodiesterase inhibitors
ATE506358T1 (de) 2-benzylpyridazinonderivate als met-kinasehemmer
ATE545417T1 (de) Pyrazoloä3,4-büpyridin-derivate als phosphodiesterasehemmer
DK2114951T3 (da) Hidtil ukendte phosphodiesterase-inhibitorer
CR10879A (es) Cyclized derivatives as eg-5 inhibitors